Home›Infectious Disease› Probiotics and postbiotics demonstrate anti-Candida activity by inhibiting growth, biofilm formation, and virulence genes
Probiotics and postbiotics demonstrate anti-Candida activity by inhibiting growth, biofilm formation, and virulence genesProbiotics and postbiotics show potential against Candida yeast infections
Frontiers in MedicinePublished September 24, 2026DOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Note that while probiotics show anti-Candida activity in preclinical models, human clinical trials are needed.
This systematic review synthesizes current evidence regarding the efficacy of probiotics (including Lactobacillus, Bifidobacterium, and Saccharomyces) and postbiotics in managing Candidiasis. The review focuses on anti-Candida activity, including the inhibition of fungal growth, adhesion, yeast-to-hyphal transition, biofilm formation, and virulence-associated gene expression. Additionally, the review explores secondary outcomes such as the production of antimicrobial metabolites, competitive exclusion, and immune modulation.
The authors report that probiotics consistently demonstrated inhibition of fungal growth and related virulence factors. Furthermore, emerging evidence suggests that postbiotics and specific probiotic strains may possess antifungal potential against non-albicans Candida species and Candida auris. These findings suggest a potential role for these interventions in managing fungal infections.
A significant limitation of the current evidence is that it is predominantly preclinical. The authors note considerable heterogeneity in probiotic strains, experimental models, and methodologies, which precluded a quantitative meta-analysis. Consequently, the clinical applicability of these findings is currently limited.
Clinical implementation requires well-designed human studies to establish strain-specific efficacy, optimal formulations, and dosing strategies. Until such data are available, the clinical utility of probiotics and postbiotics for Candidiasis remains uncertain.
How this fits prior evidence
This systematic review addresses a gap in the management of Candidiasis by evaluating the mechanisms of probiotic and postbiotic action. While prior coverage notes that probiotics may improve fatigue and pain in multiple sclerosis and reduce migraine frequency, this review specifically focuses on the antimicrobial and anti-biofilm properties of these agents against Candida species. It provides a foundational look at the mechanisms of action, though it does not yet confirm clinical outcomes in human patients.
Living with a Candida infection can be a persistent challenge. Researchers are looking closely at how probiotics—beneficial bacteria and yeast—might help manage these infections. The review found that these probiotics consistently slowed down fungal growth and stopped the yeast from forming biofilms, which are protective layers that make it harder for the body to fight the infection.
Beyond just blocking growth, the study looked at how these treatments might stop yeast from changing into a more invasive form. There is also emerging evidence that postbiotics, which are products derived from probiotics, could be effective against specific types of yeast like Candida auris.
While these results are promising, it is important to note that most of the evidence comes from early laboratory and animal studies. Because different strains of probiotics vary so much, more clinical trials in humans are needed to figure out the best dosages and specific types to use for patients.
What this means for you:
Probiotics and postbiotics show promise in lab tests against Candida, but more human trials are needed.
Common questions
What are probiotics and postbiotics?
Probiotics are beneficial bacteria and yeast, such as Lactobacillus and Bifidobacterium, that can help balance the body. Postbiotics are products derived from these probiotics. Both are being studied for their ability to stop the growth and spread of Candida yeast infections.
Can these treatments work against different types of yeast?
Yes, emerging evidence suggests that postbiotics may have antifungal potential against non-albicans Candida species and Candida auris. These are specific types of yeast that can cause infections.
Are these treatments ready to be used in clinics?
Not yet. Because most of the current evidence comes from preclinical studies, more clinical trials are needed. Doctors need to establish specific strains, dosages, and safety profiles before these can be used as routine treatments for patients.
BackgroundCandida species are among the most important opportunistic fungal pathogens responsible for superficial mucosal infections and life-threatening invasive candidiasis, particularly in immunocompromised individuals. The increasing prevalence of antifungal resistance, biofilm-associated tolerance, and the emergence of multidrug-resistant species such as Candida auris have highlighted the need for alternative or adjunctive therapeutic strategies. Probiotics have emerged as promising microbiome-based interventions owing to their ability to inhibit Candida growth, suppress virulence traits, restore microbial homeostasis, and modulate host immune responses.MethodsThis systematic review comprehensively evaluated the experimental and mechanistic evidence regarding the anti-Candida activity of probiotics and probiotic-derived products. A systematic literature search was conducted in PubMed, Scopus, and Web of Science for studies published between 1 January 2015 and 5 January 2026 in accordance with PRISMA 2020 guidelines. Studies meeting the predefined eligibility criteria were included in the qualitative synthesis.ResultsEighteen studies met the predefined eligibility criteria. Most studies investigated Lactobacillus species, followed by Bifidobacterium, Saccharomyces, and probiotic-derived metabolites or postbiotics, using predominantly in vitro models with limited in vivo evidence. Across studies, probiotics consistently demonstrated anti-Candida activity through inhibition of fungal growth, adhesion, yeast-to-hyphal transition, biofilm formation, and virulence-associated gene expression. Additional mechanisms included the production of antimicrobial metabolites, competitive exclusion, immune modulation, enhancement of epithelial barrier function, and restoration of microbial homeostasis. Emerging evidence also supports the antifungal potential of postbiotics and activity against non-albicans Candida species and Candida auris, although available evidence remains limited. Considerable heterogeneity in probiotic strains, experimental models, methodologies, and outcome measures precluded quantitative meta-analysis.ConclusionsCurrent evidence supports probiotics and postbiotics as promising microbiome-based strategies for reducing Candida pathogenicity; however, the available evidence remains predominantly preclinical. Well-designed clinical studies are required to establish strain-specific efficacy, optimal formulations, dosing strategies, safety, and therapeutic applicability before routine clinical implementation.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/view/CRD420261278363, identifier CRD420261278363.
